Literature DB >> 17429586

[Skin and mucosal ulcerations in heparin-induced thrombocytopenia (HIT) II].

D Helbig1, U Hillen, S Grabbe, J Dissemond.   

Abstract

About 0.1-2% of patients receiving heparin develop heparin-induced thrombocytopenia type II (HIT II) which is caused by antibodies directed against heparin-platelet factor 4 (PF4) complexes. Activation of thrombocytes and endothelial cells can lead to thrombocytopenia, venous and arterial thrombosis or thromboembolic events 10-14 days after the first dose. HIT II has a high mortality rate because of pulmonary emboli, cerebrovascular accidents, myocardial and limb infarctions. A 55-year-old patient with HIT II presented with arterial and venous thromboses and a silent myocardial infarction. In addition, he showed extensive skin and mucosal necrosis, an uncommon complication. Rheologic therapy with danaparoid Natrium, alprostadil alfadex and acetylsalicylic acid in combination with percutaneous transluminal angioplasties as well as local and systemic antiinflammatory therapy prevented further progression of the disease.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17429586     DOI: 10.1007/s00105-007-1300-6

Source DB:  PubMed          Journal:  Hautarzt        ISSN: 0017-8470            Impact factor:   0.751


  14 in total

1.  Determination of heparin-platelet factor 4-IgG antibodies improves diagnosis of heparin-induced thrombocytopenia.

Authors:  E Lindhoff-Last; F Gerdsen; H Ackermann; R Bauersachs
Journal:  Br J Haematol       Date:  2001-06       Impact factor: 6.998

2.  A comparison of danaparoid and lepirudin in heparin-induced thrombocytopenia.

Authors:  B Farner; P Eichler; H Kroll; A Greinacher
Journal:  Thromb Haemost       Date:  2001-06       Impact factor: 5.249

3.  Heparin-induced thrombocytopenia with thrombosis: incidence, analysis of risk factors, and clinical outcomes in 108 consecutive patients treated at a single institution.

Authors:  S Nand; W Wong; B Yuen; A Yetter; E Schmulbach; S Gross Fisher
Journal:  Am J Hematol       Date:  1997-09       Impact factor: 10.047

Review 4.  Adverse skin reactions to low molecular weight heparins: frequency, management and prevention.

Authors:  R Wütschert; P Piletta; H Bounameaux
Journal:  Drug Saf       Date:  1999-06       Impact factor: 5.606

Review 5.  Heparin-induced thrombocytopenia: clinical manifestations and management strategies.

Authors:  L Bernardo Menajovsky
Journal:  Am J Med       Date:  2005-08       Impact factor: 4.965

6.  Heparin-associated thrombocytopenia: isolation of the antibody and characterization of a multimolecular PF4-heparin complex as the major antigen.

Authors:  A Greinacher; B Pötzsch; J Amiral; V Dummel; A Eichner; C Mueller-Eckhardt
Journal:  Thromb Haemost       Date:  1994-02       Impact factor: 5.249

7.  Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin.

Authors:  T E Warkentin; M N Levine; J Hirsh; P Horsewood; R S Roberts; M Gent; J G Kelton
Journal:  N Engl J Med       Date:  1995-05-18       Impact factor: 91.245

8.  A rapid and sensitive test for diagnosing heparin-associated thrombocytopenia.

Authors:  A Greinacher; I Michels; V Kiefel; C Mueller-Eckhardt
Journal:  Thromb Haemost       Date:  1991-12-02       Impact factor: 5.249

Review 9.  [The therapy of the heparin-induced thrombosis-thrombocytopenia syndrome with immunoglobulins].

Authors:  A Prull; R Nechwatal; H Riedel; W Mäurer
Journal:  Dtsch Med Wochenschr       Date:  1992-11-27       Impact factor: 0.628

10.  Antibodies to macromolecular platelet factor 4-heparin complexes in heparin-induced thrombocytopenia: a study of 44 cases.

Authors:  J Amiral; F Bridey; M Wolf; C Boyer-Neumann; E Fressinaud; A M Vissac; E Peynaud-Debayle; M Dreyfus; D Meyer
Journal:  Thromb Haemost       Date:  1995-01       Impact factor: 5.249

View more
  1 in total

Review 1.  [Medications. A rare cause for leg ulcers].

Authors:  J Dissemond
Journal:  Hautarzt       Date:  2011-07       Impact factor: 0.751

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.